- Home
- NBBK vs FLGT Comparison
NBBK vs FLGT Comparison
Compare NBBK & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- FLGT
- Stock Information
- Founded
- NBBK 1892
- FLGT 2011
- Country
- NBBK United States
- FLGT United States
- Employees
- NBBK N/A
- FLGT N/A
- Industry
- NBBK
- FLGT Medical Specialities
- Sector
- NBBK
- FLGT Health Care
- Exchange
- NBBK Nasdaq
- FLGT Nasdaq
- Market Cap
- NBBK 687.7M
- FLGT 588.5M
- IPO Year
- NBBK N/A
- FLGT 2016
- Fundamental
- Price
- NBBK $18.76
- FLGT $20.06
- Analyst Decision
- NBBK Buy
- FLGT Buy
- Analyst Count
- NBBK 1
- FLGT 2
- Target Price
- NBBK $22.00
- FLGT $24.00
- AVG Volume (30 Days)
- NBBK 471.3K
- FLGT 214.1K
- Earning Date
- NBBK 07-23-2025
- FLGT 08-01-2025
- Dividend Yield
- NBBK N/A
- FLGT N/A
- EPS Growth
- NBBK 421.39
- FLGT N/A
- EPS
- NBBK 1.18
- FLGT N/A
- Revenue
- NBBK $169,131,000.00
- FLGT $292,448,000.00
- Revenue This Year
- NBBK N/A
- FLGT $11.79
- Revenue Next Year
- NBBK N/A
- FLGT $10.45
- P/E Ratio
- NBBK $16.05
- FLGT N/A
- Revenue Growth
- NBBK 27.71
- FLGT 1.71
- 52 Week Low
- NBBK $14.84
- FLGT $14.57
- 52 Week High
- NBBK $21.05
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- NBBK 75.82
- FLGT 49.02
- Support Level
- NBBK $17.70
- FLGT $19.68
- Resistance Level
- NBBK $17.31
- FLGT $20.37
- Average True Range (ATR)
- NBBK 0.47
- FLGT 0.58
- MACD
- NBBK 0.27
- FLGT -0.07
- Stochastic Oscillator
- NBBK 90.91
- FLGT 50.97
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.